Source author record

Carl Poelking

Carl Poelking appears in the imported research catalog. Authorship, coauthor and topic links are available while profile ownership is still unclaimed.

ResearcherUnclaimed source record

Catalog footprint

What is connected

2works
3topics
4close collaborators

Actions

Connect this record

Log in to claim

Research graph

See the researcher in context

Open full explorer

Inspect adjacent papers, topics, institutions and collaborators without losing the researcher page.

Building this map preview

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

2 published item(s)

preprint2022arXiv

3D pride without 2D prejudice: Bias-controlled multi-level generative models for structure-based ligand design

Generative models for structure-based molecular design hold significant promise for drug discovery, with the potential to speed up the hit-to-lead development cycle, while improving the quality of drug candidates and reducing costs. Data sparsity and bias are, however, two main roadblocks to the development of 3D-aware models. Here we propose a first-in-kind training protocol based on multi-level contrastive learning for improved bias control and data efficiency. The framework leverages the large data resources available for 2D generative modelling with datasets of ligand-protein complexes. The result are hierarchical generative models that are topologically unbiased, explainable and customizable. We show how, by deconvolving the generative posterior into chemical, topological and structural context factors, we not only avoid common pitfalls in the design and evaluation of generative models, but furthermore gain detailed insight into the generative process itself. This improved transparency significantly aids method development, besides allowing fine-grained control over novelty vs familiarity.

preprint2022arXiv

Meaningful machine learning models and machine-learned pharmacophores from fragment screening campaigns

Machine learning (ML) is widely used in drug discovery to train models that predict protein-ligand binding. These models are of great value to medicinal chemists, in particular if they provide case-specific insight into the physical interactions that drive the binding process. In this study we derive ML models from over 50 fragment-screening campaigns to introduce two important elements that we believe are absent in most -- if not all -- ML studies of this type reported to date: First, alongside the observed hits we use to train our models, we incorporate true misses and show that these experimentally validated negative data are of significant importance to the quality of the derived models. Second, we provide a physically interpretable and verifiable representation of what the ML model considers important for successful binding. This representation is derived from a straightforward attribution procedure that explains the prediction in terms of the (inter-)action of chemical environments. Critically, we validate the attribution outcome on a large scale against prior annotations made independently by expert molecular modellers. We find good agreement between the key molecular substructures proposed by the ML model and those assigned manually, even when the model's performance in discriminating hits from misses is far from perfect. By projecting the attribution onto predefined interaction prototypes (pharmacophores), we show that ML allows us to formulate simple rules for what drives fragment binding against a target automatically from screening data.